acid and was eluted with 4 mL of acetonitrile:water (50:50 by vol). The residue was dissolved in 0.3 mL of 50 mmol/L phosphate buffer (pH 7.4) and assayed by RIA with radioiodinated vasopressin and antiserum against synthetic vasopressin in rabbits.
For statistical evaluation, we used ANOVA, followed by Bonferroni's correction. Results are presented as mean Ϯ SD.
Nicotine gum was well-tolerated, but 2 subjects had local mouth irritation. All volunteers had significantly increased mean plasma ET-1 values within 15 min after chewing the nicotine gum (P Ͻ0.0001), whereas the vasopressin values increased 5 min after this oral nicotine administration (P Ͻ0.002) ( Table 1 ). Oral nicotine consumption was associated with significant increases in the mean pulse rate (P Ͻ0.001) and systolic (P Ͻ0.005) and diastolic (P Ͻ0.001) blood pressure 15 min after the start of nicotine gum administration, compared with the basal values: 76.2 Ϯ 2.5 beats/min, 125.5 Ϯ 8 mmHg, and 86.1 Ϯ 3.3 mmHg vs 69.7 Ϯ 2.4 beats/min, 118.3 Ϯ 2.5 mmHg, and 80.1 Ϯ 3.5 mmHg, respectively.
In addition, the correlation between ET-1 and vasopressin plasma concentrations 60 min after nicotine gum administration was statistically significant (r ϭ 0.695, P ϭ 0.038). As reported in Table 1 , plasma ET-1 and vasopressin concentrations and the hemodynamic measurements remained unchanged during the placebo experiment.
ET-1 is one of the most potent vasoconstrictors (10 times more po-tent than angiotensin II, vasopressin, and neuropeptide Y) [1] , and its expression by endothelial cells is regulated by other vasoactive agents [1, 3, 4] . Thus, vasopressin rapidly (within 5 min) induces the expression of pro-pre-endothelin-1 mRNA and secretion of ET-1 from a cultured bovine carotid endothelial cells [14] .
Our results indicate that acute nicotine consumption induces in nonsmoking healthy subjects an increase in plasma ET-1 concentrations and that this increase follows a prompt rise of plasma vasopressin. These data suggest that, at least in part, the acute consumption of nicotine stimulates the release of circulating ET-1 via vasopressin activation. Therefore, the alterations in plasma ET-1 secretion induced by nicotine consumption might contribute to the pathogenesis of several cardiovascular disorders, in view of the powerful vasoconstrictor and growth-promoting properties of the peptide. Additional studies are required to describe the effects of nicotine gum in smokers.
Biological Variation of Free and Total Carnitine in Serum of Healthy Subjects
To the Editor: Determination of carnitine (l-␤-hydroxy-␥-trimethylaminobutyric acid) in biological samples plays an important role in the diagnosis of diseases with carnitine deficiency [1] . In the past few years, and also in this Journal, several spectrophotometric methods for assaying carnitine in serum have been described [2] [3] [4] [5] [6] . To our knowledge, however, no data have been published on the biological variation of this serum analyte. For any new test, data on the biological variation generated from the healthy population may be used (a) in setting desirable performance standards or analytical goals, (b) in assessing the utility of conventional population-based reference intervals, and (c) in critically evaluating the significance of changes in serial results from an individual [7] .
To investigate the analytical and biological variation of free and total carnitine, as well as of the acyl/free carnitine ratio, we collected blood samples once a week for 4 weeks from each of 14 healthy subjects (7 men and 7 nonpregnant women, ages 21-23 years), students of Mathias Belius University. The subjects agreed to maintain current dietary habits, body weight, and exercise program (if any) for the duration of the study. The criteria of the hospital Ethics Committee were respected in this experiment.
To minimize sources of preanalytical variation, venous blood specimens were drawn between 0800 and 0900 h after ϳ12 h of fasting. The subjects remained seated for at least 20 -30 min before the blood was drawn. Usually, specimens were obtained by a single phlebotomist and with minimal stasis into Monovette Serum Gel blood-collection tubes (Sarstedt). Serum specimens for both the free and total carnitine assays were prepared and stored the same way. After clotting, each specimen was centrifuged at 1500g for 15 min and the serum obtained was eluted through Centrifree R columns (Amicon) in an angle-head rotor at 2000g for 30 min. Aliquots (800 L) of protein-free serum filtrates were stored frozen at Ϫ20°C until assayed.
Free and total carnitine concentrations were determined by a spectrophotometric enzymatic assay adapted for use on the Cobas Mira analyzer (Hoffmann-La Roche). The assay uses carnitine acetyl-transferase (CAT; EC 2.3.1.7) and 5,5-dithiobis(2nitrobenzoic acid) (DTNB) as a thiolgroup color reagent. The Cobas analyzer was programed as tworeagent chemistry with a primary reagent and an enzymatic start reagent. Diluted sample (80 L) was mixed with 200 L of the primary reagent (10 mL of 0.2 mmol/L Na 2 HPO 4 , pH 7.8, 0.2 mL of 10 mmol/L DTNB, and 0.4 mL of 15 mmol/L acetyl-CoA), and the reaction was started with 24 L of sixfold-diluted start reagent [CAT from pigeon muscle (1 mL, protein 5.3 g/L, CAT 120 kU/g protein) was diluted with 0.9 mL of phosphate buffer (0.5 mol/L, pH 7.5) to give a final concentration in start reagent of 63.6 kU/L]. All specific reagents used were from Sigma Chemical Co. The reaction mixture was incubated for 5 min at 37°C and absorbance was read at 405 nm. Calibrators containing 10 -100 mol/L of l-carnitine were prepared by programed dilutions of the stock solution. The Cobas assay was linear for carnitine concentrations up to 250 mol/L and the limit of detection was ϳ2 mol/L.
Free carnitine values were measured directly. Total carnitine was quantified after nonautomated de-esterification by alkaline hydrolysis [6] . In our hands, the analytical recovery of l-octanoylcarnitine added to serum filtrate, determined as free carnitine after hydrolysis, was 94 -105% (mean 98%, n ϭ 6). All specimens were assayed in replicate in the same analytical run.
Dixon's test was used to exclude outlying values from a single subject. The analytical (CV A ), within-subject (CV I ), and between-subject (CV G ) components of variation were calculated by nested analysis of variance [8] . Useful indices, i.e., analytical goals for imprecision (CV A Ͻ 1 ⁄2CV I ), indices of individuality (CV I /CV G ), and critical differences required for significant (P Յ0.05) changes in serial results [2.77 (CV A 2 ϩ CV I 2 ) 1/2 ], were also obtained [7] . The significance of the differences between means and between variances was evaluated by using the unpaired t-test and the Fisher F-test, respectively.
The results for free carnitine, total carnitine, and the acyl/free carnitine ratio are summarized in Table 1 . As expected, men showed higher means for these analytes than women. However, this difference was significant only for the total carnitine concentration (P Ͻ0.02). All values obtained for each subject fell within our laboratory's reference intervals for free and total carnitine.
In several clinical conditions, an acyl/free carnitine ratio should be calculated from the two carnitine assays (acylcarnitine ϭ total carnitine Ϫ free carnitine) [9, 10] . Our values for this ratio are somewhat higher than those found for healthy subjects in several other laboratories Men and women, n ϭ 7 each; carnitine concentrations, mol/L. a Significantly different from the concentration in men (P Ͻ0.02, unpaired t-test).
[ [11] [12] [13] , probably because of different methodologies used, different physiological characteristics of the subjects, or both. Replicate analyses for each sample were used to investigate within-run analytical variation. The CV A values of the analytical methods for free and total carnitine are lower than the respective goals, but those of the acyl/free carnitine ratio are greater. The high CV A component of carnitine assays could limit the clinical utility of the acyl/free carnitine ratio [7] .
The mean CV I value for each carnitine quantity is Ͻ12.3%; for men and women, the acyl/free carnitine ratio is the most variable quantity. The relative distribution of free carnitine and carnitine esters varies according to fasting status, adiposity, renal function, and muscular exercise [11] . Nevertheless, these data indicate the existence of a reliable homeostatic mechanism in steady-state conditions. The CV G values indicate moderate variation in carnitine concentrations between healthy subjects. No significant differences between men and women were observed in within-or between-subject variances for any of the quantities studied.
Indices of individuality were Ͻ1.4 for each of the carnitine groups, meaning that individual results are more useful than population-based data [7] . For diagnosis and screening, however, free carnitine values Ͻ20 mol/L and total carnitine Յ30 mol/L, determined by nonradioenzymatic methods, are considered to indicate carnitine deficiency [4] . In carnitine-deficient patients, a low free carnitine concentration in serum is often associated with an increased acyl/free carnitine ratio [4, 9 -11] .
Finally, the critical differences obtained in this study, calculated from the mean CV I values, are also shown ( Table 1 ). For free and total carnitine the critical difference was less than that for the acyl/free carnitine ratio. The former assays may therefore be more suitable for monitoring purposes, especially in carnitine supplementation therapy. However, the critical differences presented here are only a guide to clinical practice; other laboratories should take into consideration their own between-day imprecision of carnitine assays.
